Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems, including the Revio, Vega, and Sequel instruments, which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips. Its portfolio also includes consumable products such as single molecule real-time (SMRT) technology, long-read sequencing, and various reagent kits for specific workflows. These include preparation kits to convert DNA into SMRTbell double-stranded DNA library formats, binding kits with modified DNA polymerase, and sequencing kits with phospholinked nucleotides. Additionally, the company offers short-read sequencing and the Onso instrument. Pacific Biosciences serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies.

Pacific Biosciences of California, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PACB. The company's stock is traded in US Dollars (USD). As a US-based company, its financial reporting and stock transactions are conducted in USD, which is the standard currency for companies listed on US exchanges.

Pacific Biosciences of California, Inc. operates in the Healthcare sector and is classified under the Medical Devices industry. This means the company develops and manufactures medical devices, specifically sequencing systems and related consumables used for genetic analysis. The Medical Devices industry includes companies that produce equipment, instruments, and supplies for diagnostic, therapeutic, and research purposes in healthcare and life sciences.

Pacific Biosciences of California, Inc. is headquartered in the United States. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company also has a collaboration with DNAstack Inc. to provide a federated dataset of HiFi whole genome sequencing data.

Pacific Biosciences generates revenue primarily through the sale of its sequencing systems and consumable products. The company's sequencing systems include the Revio, Vega, and Sequel instruments, which are used for single-molecule real-time sequencing. Consumables include SMRT technology, long-read sequencing, and various reagent kits such as preparation kits, binding kits, and sequencing kits. Additionally, the company offers short-read sequencing and the Onso instrument. By providing both instruments and the necessary consumables for their operation, Pacific Biosciences creates a recurring revenue stream from consumable sales. The company serves a diverse customer base across multiple regions, including academic institutions, research labs, hospitals, and pharmaceutical companies.